Havas merges transatlantic duo of digital shops

Share this article:
Havas is merging two digital shops, Euro RSCG Life 4D and Creative Lynx, to form Havas Lynx, a transatlantic full service group which will serve as a mini-network alongside Havas Life and Health4Brands.

Havas Lynx will be led in the US by Larry Mickelberg, who will also serve as president of the group, and in Europe by a quartet of co-directors – Neil Martin, David Hunt, Dave Whittingham and Steve Nicholas.

“While we have a full service offering, the nature of the work we do is much more about creating liquid experiences that traverse the health ecosystem – technologies, places and health needs – as opposed to classic brand positioning and messaging,” said Mickelberg, who is chief digital officer and partner at Havas Health. Both he and the quartet of UK directors will report to Havas Health global CEOs Donna Murphy and Doug Burcin.  

The combined group will boast a staff of around 300 and a client roster including Novartis, AstraZeneca and Janssen, for which Creative Lynx developed the pioneering Psoriasis360 social media campaign.

Havas acquired Manchester, UK-based digital health shop Creative Lynx in June. The 25-year-old UK shop brought to Havas a staff of 100 and satellite offices in London and Switzerland.

The new group is far smaller than its siblings, Havas Life and Health4Brands, and will seek to play beyond the pharma sector, said Mickelberg.

“We will certainly have a strong base in pharmaceuticals and will increasingly also target devices, mhealth and health services, along with retailers, gyms, manufacturers, and other new entrants into the new health ecosystem,” said Mickelberg.
Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...